The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox.. A 1999 review published by a chemist using the pseudonym John Q. Beagle suggested the potency of 4-MeO-PCP in man was reduced relative to PCP. Two years later, Beagle published a detailed description of the synthesis and qualitative effects of 4-MeO-PCP which he said possessed 70% of the potency of PCP..
4-MeO-PCP was the first arylcyclohexylamine research chemical to be sold online. It was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-MeO-PCP and Methoxetamine (MXE)...
4-MeO-PCP, or 4-Methoxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. 4-MeO-PCP contains cyclohexane, a six member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring (a nitrogenous six member ring) bonded at its nitrogen group. The other ring is an aromatic phenyl ring substituted at R4 with a methoxy group. 4-MeO-PCP is a PCPderivative, and structurally analogous to 3-MeO-PCP.
4-MeO-PCP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”
4-MeO-PCP has lower affinity for the NMDA receptor than PCP, but higher affinity than ketamine. It is orally active in a dosage range similar to ketamine with some users requiring doses in excess of 100mg for desired effects... Users have reported substantial differences in active dose; these discrepancies can be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market.. Though 4-MeO-PCP has been suggested to possess dopaminergic activity, it is a relatively selective ligand for the NMDA receptor without appreciable affinity for the dopamine transporter..
|Threshold||25 – 75 mg|
|Light||75 – 100 mg|
|Common||100 – 170 mg|
|Strong||170 – 250 mg|
|Heavy||250 mg +|
|Total||12 – 20 hours|
|Onset||45 – 120 minutes|
|Come up||1 – 2 hours|
|Peak||3 – 7 hours|
|Offset||6 – 10 hours|
|After effects||6+ hours|
|DISCLAIMER: PW’s dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.|